CA3080937A1 - Mutational analysis of plasma dna for cancer detection - Google Patents

Mutational analysis of plasma dna for cancer detection

Info

Publication number
CA3080937A1
CA3080937A1 CA3080937A CA3080937A CA3080937A1 CA 3080937 A1 CA3080937 A1 CA 3080937A1 CA 3080937 A CA3080937 A CA 3080937A CA 3080937 A CA3080937 A CA 3080937A CA 3080937 A1 CA3080937 A1 CA 3080937A1
Authority
CA
Canada
Prior art keywords
cancer
cancer detection
plasma dna
mutational analysis
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3080937A
Other languages
English (en)
French (fr)
Inventor
Rossa Wai Kwun Chiu
Yuk Ming Dennis Lo
Kwan Chee Chan
Peiyong Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinese University of Hong Kong CUHK
Original Assignee
Chinese University of Hong Kong CUHK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinese University of Hong Kong CUHK filed Critical Chinese University of Hong Kong CUHK
Publication of CA3080937A1 publication Critical patent/CA3080937A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C12Q2539/107—Representational Difference Analysis [RDA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3080937A 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection Pending CA3080937A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261662878P 2012-06-21 2012-06-21
US61/662,878 2012-06-21
US201261682725P 2012-08-13 2012-08-13
US61/682,725 2012-08-13
US201261695795P 2012-08-31 2012-08-31
US61/695,795 2012-08-31
US201261711172P 2012-10-08 2012-10-08
US61/711,172 2012-10-08
US13/801,748 US11261494B2 (en) 2012-06-21 2013-03-13 Method of measuring a fractional concentration of tumor DNA
US13/801,748 2013-03-13
CA2876327A CA2876327C (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2876327A Division CA2876327C (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Publications (1)

Publication Number Publication Date
CA3080937A1 true CA3080937A1 (en) 2013-12-27

Family

ID=52274459

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3080937A Pending CA3080937A1 (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection
CA2876327A Active CA2876327C (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2876327A Active CA2876327C (en) 2012-06-21 2013-06-14 Mutational analysis of plasma dna for cancer detection

Country Status (18)

Country Link
US (3) US11261494B2 (enExample)
EP (4) EP4512907A3 (enExample)
JP (4) JP6371280B2 (enExample)
KR (7) KR102656030B1 (enExample)
CN (3) CN104662168B (enExample)
AU (4) AU2013278994C1 (enExample)
CA (2) CA3080937A1 (enExample)
DK (2) DK2864501T3 (enExample)
EA (2) EA202092900A3 (enExample)
ES (2) ES2894479T3 (enExample)
HU (1) HUE056915T2 (enExample)
IL (5) IL298810B2 (enExample)
MX (3) MX360264B (enExample)
PT (1) PT3456843T (enExample)
SG (2) SG10201808217WA (enExample)
TW (4) TWI636255B (enExample)
WO (1) WO2013190441A2 (enExample)
ZA (1) ZA201409281B (enExample)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3892736A1 (en) 2007-07-23 2021-10-13 The Chinese University of Hong Kong Determining a nucleic acid sequence imbalance
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
KR20190002733A (ko) 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR102393608B1 (ko) 2012-09-04 2022-05-03 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US20130309666A1 (en) 2013-01-25 2013-11-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP4253558B1 (en) * 2013-03-15 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
WO2014144092A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
WO2015073711A1 (en) 2013-11-13 2015-05-21 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
EP3378952B1 (en) 2013-12-28 2020-02-05 Guardant Health, Inc. Methods and systems for detecting genetic variants
EP3134541B1 (en) 2014-04-21 2020-08-19 Natera, Inc. Detecting copy number variations (cnv) of chromosomal segments in cancer
US12492429B2 (en) * 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11062789B2 (en) 2014-07-18 2021-07-13 The Chinese University Of Hong Kong Methylation pattern analysis of tissues in a DNA mixture
US20170211143A1 (en) * 2014-07-25 2017-07-27 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
US10102337B2 (en) 2014-08-06 2018-10-16 Nugen Technologies, Inc. Digital measurements from targeted sequencing
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
PT3198026T (pt) * 2014-08-07 2020-01-16 Pharmassist Ltd Método de determinação do estado mutacional de pik3ca numa amostra
EP3191628B1 (en) 2014-09-12 2022-05-25 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acids
ES2989276T3 (es) * 2014-12-05 2024-11-25 Found Medicine Inc Análisis multigénico de muestras tumorales
WO2016094853A1 (en) 2014-12-12 2016-06-16 Verinata Health, Inc. Using cell-free dna fragment size to determine copy number variations
ES2923602T3 (es) * 2014-12-31 2022-09-28 Guardant Health Inc Detección y tratamiento de enfermedades que muestran heterogeneidad celular de enfermedad y sistemas y métodos para comunicar los resultados de las pruebas
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
EP4012715B1 (en) 2015-02-10 2025-09-24 The Chinese University Of Hong Kong Detecting mutations for cancer screening and fetal analysis
CA2983833C (en) * 2015-05-01 2024-05-14 Guardant Health, Inc. Diagnostic methods
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
CN104894268B (zh) * 2015-06-05 2018-02-09 上海美吉生物医药科技有限公司 定量样本中源自细胞凋亡的dna浓度的方法及其应用
WO2017002943A1 (ja) * 2015-07-01 2017-01-05 学校法人慶應義塾 癌組織の不均一性マーカー及びその使用
JP2017016665A (ja) * 2015-07-03 2017-01-19 国立大学法人東北大学 配列のデータからの変異情報の選択方法、システム、及び、コンピュータプログラム
EP3739061B1 (en) 2015-07-20 2022-03-23 The Chinese University Of Hong Kong Methylation pattern analysis of haplotypes in tissues in dna mixture
CN108026572B (zh) 2015-07-23 2022-07-01 香港中文大学 游离dna的片段化模式的分析
CN115433769A (zh) 2015-08-12 2022-12-06 香港中文大学 血浆dna的单分子测序
CN108475296A (zh) 2015-08-25 2018-08-31 南托米克斯有限责任公司 用于对转移进行遗传分析的系统和方法
JP2019507585A (ja) 2015-12-17 2019-03-22 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａの分析による腫瘍遺伝子コピー数を決定するための方法
WO2017136603A1 (en) * 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
US10095831B2 (en) 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
KR101810528B1 (ko) * 2016-03-29 2017-12-21 한국과학기술원 단백질을 변화시키지 않는 암 돌연변이의 기능적 recurrence를 구하는 방법 및 장치
EP4488686A3 (en) 2016-04-14 2025-04-30 Guardant Health, Inc. Methods for early detection of cancer
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
WO2017191076A1 (en) 2016-05-01 2017-11-09 Genome Research Limited Method of characterising a dna sample
GB2555765A (en) 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
CN105969856B (zh) * 2016-05-13 2019-11-12 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测方法
CN105969656B (zh) * 2016-05-13 2019-09-10 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测及分析平台
CN106355045B (zh) * 2016-08-30 2019-03-15 天津诺禾致源生物信息科技有限公司 一种基于扩增子二代测序小片段插入缺失检测的方法及装置
EP3792922A1 (en) * 2016-09-30 2021-03-17 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
SG11201903509QA (en) 2016-10-24 2019-05-30 Univ Hong Kong Chinese Methods and systems for tumor detection
GB201618485D0 (en) * 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CN114774520B (zh) * 2016-11-17 2025-09-05 阅尔基因技术（苏州）有限公司 检测肿瘤发展的系统和方法
WO2018099418A1 (en) 2016-11-30 2018-06-07 The Chinese University Of Hong Kong Analysis of cell-free dna in urine and other samples
EP3552128B1 (en) * 2016-12-08 2025-07-23 Life Technologies Corporation Methods for detecting mutation load from a tumor sample
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
MY197535A (en) 2017-01-25 2023-06-21 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
US12492430B2 (en) 2017-04-11 2025-12-09 Tecan Genomics, Inc. Library quantitation and qualification
US11342047B2 (en) 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
EP4461826A3 (en) * 2017-05-16 2025-05-14 Guardant Health, Inc. Identification of somatic or germline origin for cell-free dna
KR102145417B1 (ko) * 2017-05-24 2020-08-19 지니너스 주식회사 무세포 핵산으로부터 수득된 서열 분석 데이터에 대한 배경 대립인자의 빈도 분포를 생성하는 방법 및 이를 이용하여 무세포 핵산으로부터 변이를 검출하는 방법
DK3658684T3 (da) 2017-07-26 2023-10-09 Univ Hong Kong Chinese Forbedring af cancerscreening ved hjælp af cellefrie, virale nukleinsyrer
EP3682035B1 (en) * 2017-09-15 2025-02-05 The Regents of the University of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
CA3075932A1 (en) * 2017-09-20 2019-03-28 Guardant Health, Inc. Methods and systems for differentiating somatic and germline variants
WO2019074933A2 (en) * 2017-10-10 2019-04-18 Nantomics, Llc COMPLETE GENOMIC TRANSCRIPTOM ANALYSIS OF A PANEL OF NORMAL-TUMOR GENES FOR ENHANCED PRECISION IN PATIENTS WITH CANCER
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
KR102356323B1 (ko) * 2017-11-30 2022-01-26 일루미나, 인코포레이티드 서열 변이체 콜에 대한 검증방법 및 시스템
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US20190249229A1 (en) * 2018-02-12 2019-08-15 Nant Holdings Ip, Llc Bam signatures from liquid and solid tumors and uses therefor
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
WO2019204360A1 (en) * 2018-04-16 2019-10-24 Grail, Inc. Systems and methods for determining tumor fraction in cell-free nucleic acid
US11482303B2 (en) 2018-06-01 2022-10-25 Grail, Llc Convolutional neural network systems and methods for data classification
US20190385700A1 (en) * 2018-06-04 2019-12-19 Guardant Health, Inc. METHODS AND SYSTEMS FOR DETERMINING The CELLULAR ORIGIN OF CELL-FREE NUCLEIC ACIDS
EP3802923A4 (en) 2018-06-11 2022-03-16 Foundation Medicine, Inc. COMPOSITIONS AND METHODS FOR ASSESSING GENOMIC ALTERATIONS
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN120193081A (zh) * 2018-07-23 2025-06-24 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
KR102890173B1 (ko) 2018-11-01 2025-11-21 일루미나, 인코포레이티드 체세포 변이 검출을 위한 방법 및 조성물
KR20210089240A (ko) * 2018-11-13 2021-07-15 미리어드 제네틱스, 인크. 체세포성 돌연변이를 위한 방법 및 시스템 그리고 그 용도
US11581062B2 (en) 2018-12-10 2023-02-14 Grail, Llc Systems and methods for classifying patients with respect to multiple cancer classes
ES2968457T3 (es) 2018-12-19 2024-05-09 Univ Hong Kong Chinese Características de los extremos del ADN extracelular circulante
WO2020132499A2 (en) * 2018-12-21 2020-06-25 Grail, Inc. Systems and methods for using fragment lengths as a predictor of cancer
CN109616198A (zh) * 2018-12-28 2019-04-12 陈洪亮 仅用于肝癌单一癌种筛查的特异甲基化检测位点组合的选取方法
CN109686414A (zh) * 2018-12-28 2019-04-26 陈洪亮 仅用于肝癌筛查的特异甲基化检测位点组合的选取方法
CN109817279B (zh) * 2019-01-18 2022-11-04 臻悦生物科技江苏有限公司 肿瘤突变负荷的检测方法、装置、存储介质及处理器
KR102381252B1 (ko) * 2019-02-19 2022-04-01 주식회사 녹십자지놈 혈중 무세포 dna 기반 간암 치료 예후예측 방법
CN109841265B (zh) * 2019-02-22 2021-09-21 清华大学 使用片段化模式确定血浆游离核酸分子组织来源的方法和系统及应用
CN109920480B (zh) * 2019-03-14 2020-02-21 深圳市海普洛斯生物科技有限公司 一种校正高通量测序数据的方法和装置
CN111755075B (zh) * 2019-03-28 2023-09-29 深圳华大生命科学研究院 对免疫组库高通量测序样本间序列污染进行过滤的方法
US12437839B2 (en) 2019-05-03 2025-10-07 Ultima Genomics, Inc. Methods for detecting nucleic acid variants
WO2020227137A1 (en) 2019-05-03 2020-11-12 Ultima Genomics, Inc. Methods for detecting nucleic acid variants
EP3969617A4 (en) * 2019-05-17 2023-08-16 Ultima Genomics, Inc. Methods and systems for detecting residual disease
AU2020279752A1 (en) * 2019-05-20 2022-01-06 Foundation Medicine, Inc. Systems and methods for evaluating tumor fraction
CN111223525A (zh) * 2020-01-07 2020-06-02 广州基迪奥生物科技有限公司 一种肿瘤外显子测序数据分析方法
CN113275053A (zh) 2020-02-03 2021-08-20 帝肯基因组学公司 试剂存储系统
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
JP7022861B1 (ja) * 2021-06-25 2022-02-18 株式会社日立パワーソリューションズ アレイ型超音波送受信装置
AU2022300887A1 (en) * 2021-06-30 2024-01-25 Memorial Hospital For Cancer And Allied Diseases Detection of somatic mutational signatures from whole genome sequencing of cell-free dna
WO2023284260A1 (zh) * 2021-07-12 2023-01-19 广州燃石医学检验所有限公司 基于血液测序的肿瘤内异质性的评估方法及其用于预测免疫疗法的应答
KR20230085239A (ko) * 2021-12-06 2023-06-14 주식회사 지씨지놈 혈중 무세포 dna 기반 유방암 치료 예후예측 방법
CN115064212B (zh) * 2022-06-24 2023-03-14 哈尔滨星云生物信息技术开发有限公司 基于wgs数据的预设区域人群肿瘤特异突变识别方法
EP4547869A1 (en) 2022-06-29 2025-05-07 Raman Govindarajan Method for detecting cancer susceptibility, early detection and predicting cancer behaviour
KR20240051739A (ko) * 2022-10-13 2024-04-22 인하대학교 산학협력단 cfDNA의 구조 변이 서열 검출을 통한 미세잔존질환 진단 방법
CN117012274B (zh) * 2023-10-07 2024-01-16 北京智因东方转化医学研究中心有限公司 基于高通量测序识别基因缺失的装置

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009505A (pt) 1999-04-02 2002-06-11 Corixa Corp Compostos e processos para terapia e diagnóstico de câncer de pulmão
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
JP2005514956A (ja) 2002-01-18 2005-05-26 ジェンザイム・コーポレーション 胎児ｄｎａの検出および対立遺伝子の定量化のための方法
EP2292787B1 (en) 2002-05-10 2017-03-22 City of Hope Pyrophosphorolysis activated polymerization (PAP)
US7704687B2 (en) 2002-11-15 2010-04-27 The Johns Hopkins University Digital karyotyping
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
EP1599608A4 (en) 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal DNA and fetal cell marker in maternal plasma or serum
PL201608B1 (pl) 2003-06-13 2009-04-30 Cezary Cybulski Sposób i zestaw do wykrywania wysokiej genetycznie uwarunkowanej predyspozycji do raka prostaty oraz zastosowanie zmiany germinalnej w obrębie genu NBS1
ATE435301T1 (de) 2003-10-16 2009-07-15 Sequenom Inc Nicht invasiver nachweis fötaler genetischer merkmale
EP1751306A1 (en) 2004-04-30 2007-02-14 Yale University Methods and compositions for cancer diagnosis
US7645576B2 (en) * 2005-03-18 2010-01-12 The Chinese University Of Hong Kong Method for the detection of chromosomal aneuploidies
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
TR201910868T4 (tr) 2006-02-02 2019-08-21 Univ Leland Stanford Junior Dijital analizle invazif olmayan fetal genetik tarama.
WO2007100911A2 (en) 2006-02-28 2007-09-07 University Of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
WO2008024009A1 (en) 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung
EP2164984A2 (en) 2007-05-25 2010-03-24 Decode Genetics EHF. Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP3892736A1 (en) 2007-07-23 2021-10-13 The Chinese University of Hong Kong Determining a nucleic acid sequence imbalance
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
WO2009051842A2 (en) * 2007-10-18 2009-04-23 The Johns Hopkins University Detection of cancer by measuring genomic copy number and strand length in cell-free dna
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
HUE031848T2 (en) * 2008-09-20 2017-08-28 Univ Leland Stanford Junior Non-invasive diagnosis of fetal aneuploidy by sequencing
US8835110B2 (en) * 2008-11-04 2014-09-16 The Johns Hopkins University DNA integrity assay (DIA) for cancer diagnostics, using confocal fluorescence spectroscopy
US20100136560A1 (en) 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
WO2010091046A2 (en) * 2009-02-03 2010-08-12 President & Fellows Of Harvard College Systems and methods for high throughput, high fidelity, single molecule nucleic acid sequencing using time multiplexed excitation
WO2010112316A1 (en) 2009-03-31 2010-10-07 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Method for diagnosis of cancer and monitoring of cancer treatments
WO2011038507A1 (en) 2009-10-02 2011-04-07 Centre For Addiction And Mental Health Method for analysis of dna methylation profiles of cell-free circulating dna in bodily fluids
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
HUE061110T2 (hu) 2009-11-05 2023-05-28 Univ Hong Kong Chinese Magzati genomelemzés anyai biológiai mintából
MX357692B (es) 2009-11-06 2018-07-19 Univ Hong Kong Chinese Analisis genomico a base de tamaño.
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
EP4074838A1 (en) 2010-01-19 2022-10-19 Verinata Health, Inc. Novel protocol for preparing sequencing libraries
US10662474B2 (en) 2010-01-19 2020-05-26 Verinata Health, Inc. Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing
EP2536854B1 (en) 2010-02-18 2017-07-19 The Johns Hopkins University Personalized tumor biomarkers
EP2426217A1 (en) * 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
SG190344A1 (en) 2010-11-30 2013-06-28 Univ Hong Kong Chinese Detection of genetic or molecular aberrations associated with cancer
GB2485635B (en) 2011-07-26 2012-11-28 Verinata Health Inc Method for determining the presence or absence of different aneuploidies in a sample
JP6073902B2 (ja) 2011-10-06 2017-02-01 セクエノム， インコーポレイテッド 遺伝的変異の非侵襲的評価のための方法およびプロセス
WO2013060762A1 (en) * 2011-10-25 2013-05-02 Roche Diagnostics Gmbh Method for diagnosing a disease based on plasma-dna distribution
US10214775B2 (en) 2011-12-07 2019-02-26 Chronix Biomedical Prostate cancer associated circulating nucleic acid biomarkers
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
WO2013138510A1 (en) 2012-03-13 2013-09-19 Patel Abhijit Ajit Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
KR102393608B1 (ko) 2012-09-04 2022-05-03 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US20160186267A1 (en) 2013-02-21 2016-06-30 Toma Biosciences, Inc. Methods, compositions, and kits for nucleic acid analysis
EP3409791B1 (en) 2013-03-15 2021-06-30 Verinata Health, Inc. Generating cell-free dna libraries directly from blood
US10174375B2 (en) 2013-09-20 2019-01-08 The Chinese University Of Hong Kong Sequencing analysis of circulating DNA to detect and monitor autoimmune diseases
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
US20170211143A1 (en) 2014-07-25 2017-07-27 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same

Also Published As

Publication number Publication date
ES2687847T3 (es) 2018-10-29
CN107779506A (zh) 2018-03-09
IL235967A0 (en) 2015-01-29
CN104662168A (zh) 2015-05-27
JP2018191640A (ja) 2018-12-06
US20140100121A1 (en) 2014-04-10
IL278867B2 (en) 2023-05-01
KR101884909B1 (ko) 2018-08-02
KR20240049635A (ko) 2024-04-16
EP3919627B1 (en) 2024-10-30
KR20180088922A (ko) 2018-08-07
IL278867A (en) 2021-01-31
EA202092900A3 (ru) 2021-06-30
SG11201408113QA (en) 2015-01-29
CN107779506B (zh) 2022-07-15
KR20200035507A (ko) 2020-04-03
MX2014016058A (es) 2015-04-10
AU2022209294A1 (en) 2022-08-25
KR102237923B1 (ko) 2021-04-08
HK1204013A1 (en) 2015-11-06
JP2015527057A (ja) 2015-09-17
IL311127A (en) 2024-04-01
TW202328458A (zh) 2023-07-16
CA2876327A1 (en) 2013-12-27
EP3456843A1 (en) 2019-03-20
KR20150032708A (ko) 2015-03-27
IL235967B (en) 2019-09-26
AU2020200122B2 (en) 2022-05-19
KR102096611B1 (ko) 2020-04-02
JP6371280B2 (ja) 2018-08-08
EP3919627C0 (en) 2024-10-30
EP2864501A4 (en) 2016-03-16
IL278867B1 (en) 2023-01-01
EP2864501B1 (en) 2018-08-08
KR102656030B1 (ko) 2024-04-08
AU2013278994B2 (en) 2017-04-06
US20190264291A1 (en) 2019-08-29
TWI803505B (zh) 2023-06-01
JP7408161B2 (ja) 2024-01-05
CA2876327C (en) 2020-09-29
KR102720785B1 (ko) 2024-10-22
DK2864501T3 (en) 2018-11-05
SG10201808217WA (en) 2018-10-30
JP2021191280A (ja) 2021-12-16
TWI636255B (zh) 2018-09-21
EA202092900A2 (ru) 2021-03-31
WO2013190441A3 (en) 2014-02-27
AU2017204558A1 (en) 2017-07-27
EA201500027A1 (ru) 2015-05-29
MX360264B (es) 2018-10-26
AU2013278994C1 (en) 2019-12-12
KR20220038181A (ko) 2022-03-25
AU2020200122A1 (en) 2020-01-30
EP3456843B1 (en) 2021-07-28
HK1205533A1 (en) 2015-12-18
CN104662168B (zh) 2017-12-05
TWI786428B (zh) 2022-12-11
IL298810A (en) 2023-02-01
TW201920952A (zh) 2019-06-01
US20180202003A1 (en) 2018-07-19
IL311127B1 (en) 2024-11-01
KR102375645B1 (ko) 2022-03-17
IL298810B1 (en) 2024-04-01
DK3456843T3 (da) 2021-10-25
IL268645A (en) 2019-10-31
TW201403066A (zh) 2014-01-16
KR20210040464A (ko) 2021-04-13
CN113151474A (zh) 2021-07-23
EP4512907A3 (en) 2025-05-14
KR20230052998A (ko) 2023-04-20
HK1246830A1 (zh) 2018-09-14
MX2023001154A (es) 2023-02-22
IL311127B2 (en) 2025-03-01
US11261494B2 (en) 2022-03-01
IL298810B2 (en) 2024-08-01
AU2017204558B2 (en) 2019-10-10
EP3919627A1 (en) 2021-12-08
JP6930948B2 (ja) 2021-09-01
AU2013278994A1 (en) 2015-01-29
WO2013190441A2 (en) 2013-12-27
JP2024026360A (ja) 2024-02-28
TW202122796A (zh) 2021-06-16
KR102521842B1 (ko) 2023-04-14
HUE056915T2 (hu) 2022-03-28
ES2894479T3 (es) 2022-02-14
ZA201409281B (en) 2017-08-30
PT3456843T (pt) 2021-10-26
MX2018013085A (es) 2021-11-16
EP4512907A2 (en) 2025-02-26
EP2864501A2 (en) 2015-04-29
EA037292B1 (ru) 2021-03-05

Similar Documents

Publication Publication Date Title
CA3080937A1 (en) Mutational analysis of plasma dna for cancer detection
MY169852A (en) Detection of genetic or molecular aberrations associated with cancer
WO2014151764A3 (en) Methods and compositions for classification of samples
WO2020023420A3 (en) Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
Angeles et al. Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
EP4279612A3 (en) Analysis of fragmentation patterns of cell-free dna
WO2012051208A3 (en) Identifying rearrangements in a sequenced genome
EP4553840A3 (en) Systems and methods for analyzing nucleic acid
WO2013036941A3 (en) Automated sample handling instrumentation, systems, processes, and methods
EP4484572A3 (en) Identification and use of circulating nucleic acid tumor markers
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
WO2015130696A8 (en) Reduction of bias in genomic coverage measurements
EP4234723A3 (en) Enhancement of cancer screening using cell-free viral nucleic acids
BR112015000018A2 (pt) método e aparelho para determinar as contagens de células brancas do sangue
EP2302377A3 (en) Blood cell counter, diagnosis support method, and computer program product
WO2013036754A3 (en) Methods and compositions for diagnosis of ovarian cancer
WO2012078288A3 (en) Methods of determining risk of adverse outcomes in acute myeloid leukemia
IN2015DN02927A (enExample)
MY199897A (en) Accurate quantification of fetal dna fraction by shallow-depth sequencing of maternal plasma dna
IN2015DN01608A (enExample)
WO2012040500A3 (en) Direct blood assay for detection of circulating microrna in cancer patients
Heestermans et al. Liquid biopsies as non-invasive tools for mutation profiling in multiple myeloma: application potential, challenges, and opportunities
Doyle et al. Studying cancer genomics through next-generation DNA sequencing and bioinformatics
WO2012038744A3 (en) Detecting mutations associated with renal cancer in a pbrm1 gene

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200515

EEER Examination request

Effective date: 20200515

EEER Examination request

Effective date: 20200515

EEER Examination request

Effective date: 20200515

EEER Examination request

Effective date: 20200515

EEER Examination request

Effective date: 20200515